Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Cardiorenal syndrome
Cardiology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Time-critical presentation
Refractory pulmonary oedema, severe hyperkalaemia, severe metabolic acidosis, uraemic complications, anuria/rapidly worsening AKI or shock requires immediate senior HF, renal and critical-care assessment; do not delay renal-replacement referral for an isolated creatinine threshold.
Overview
Interpret concurrent heart and kidney dysfunction by congestion, perfusion and time course, preserve beneficial heart-failure therapy where safe and recognise dialysis-level emergencies.
A creatinine value cannot distinguish underfilling from congestive nephropathy. The decision rests on JVP/oedema, BP and perfusion, urine output, weight/diuretic response, urinalysis and the trajectory of renal and cardiac markers.
The therapeutic tension is real: diuretics and renin–angiotensin–aldosterone drugs can change creatinine, yet unresolved congestion and withdrawal of prognostic HF therapy can be more harmful. Reassess physiology before changing the prescription.
NICE AKI management focuses on identifying cause, stopping avoidable renal insults, adjusting drug doses and referring for renal replacement based on refractory complications rather than creatinine alone.
Key points
Cardiorenal syndrome describes bidirectional heart–kidney dysfunction; identify acute versus chronic change and whether congestion, low perfusion, drugs, sepsis or intrinsic renal disease dominates.
Raised venous pressure is a major renal insult in decompensated HF; a congested patient with rising creatinine may still need effective decongestion.
NICE does not recommend loop diuretics to treat AKI itself, but does recommend considering them for fluid overload or oedema while renal function is recovering or awaiting renal replacement.
Aetiology
01
Acute decompensated heart failure
Left- or right-sided decompensation raises venous and intra-abdominal pressure, impeding renal drainage. This congestive phenotype can reduce filtration despite an apparently adequate arterial blood pressure.
02
Low cardiac output or hypotension
Advanced ventricular failure, cardiogenic shock or a major arrhythmia can reduce renal perfusion. Abrupt blood-pressure falls, bleeding or excessive fluid removal may worsen this low-flow mechanism.
03
Chronic heart and kidney disease
Longstanding heart failure and chronic kidney disease reinforce sodium retention, neurohormonal activation and vascular dysfunction. Diabetes and hypertension commonly contribute to both organs' declining reserve.
04
Superimposed renal stress
Sepsis, dehydration, urinary obstruction, contrast exposure and nephrotoxic or potassium-raising medicines can precipitate deterioration. Their contribution should be assessed rather than attributing every renal change to heart failure.
Pathophysiology
1
Initial organ dysfunction
Impaired cardiac output or primary renal dysfunction activates sympathetic, renin–angiotensin–aldosterone and vasopressin pathways. These responses initially defend pressure and circulating volume but increase cardiac and renal workload.
2
Sodium and water retention
Neurohormonal signalling increases tubular sodium and water reabsorption. Expanding plasma and interstitial volume raises cardiac filling pressures and central venous pressure, promoting oedema and renal congestion.
3
Filtration falls
Raised renal venous and interstitial pressure reduces the gradient across the kidney. In advanced disease, reduced forward flow and impaired autoregulation add arterial hypoperfusion, further lowering filtration.
4
Bidirectional deterioration
Worsening renal function limits salt, water, acid and potassium excretion, aggravating congestion and treatment toxicity. Persistent cardiac loading and renal injury then sustain a self-reinforcing cycle.
Clinical features and red flags
Congestive cardiorenal syndrome
Raised JVP, oedema/ascites, weight gain and hepatic congestion with falling eGFR; often needs decongestion despite renal concern.
Low-output renal hypoperfusionRed flag
Hypotension, cool peripheries, oliguria and rising lactate/creatinine; diuretic escalation alone may worsen perfusion.
NICE AKI change
Creatinine rise at least 26 micromol/L within 48 hours, at least 50% within 7 days, or urine output below 0.5 mL/kg/hour for more than 6 hours supports AKI detection.
Intrinsic or obstructive kidney disease
Active urine sediment, heavy protein/haematuria, flank/bladder symptoms, hydronephrosis or renal decline out of proportion to haemodynamics needs a parallel renal work-up.
Hyperkalaemia toxicityRed flag
Weakness, conduction delay, bradyarrhythmia or broad-complex rhythm with high potassium is an immediate treatment emergency.
Renal-replacement indicationRed flag
Refractory hyperkalaemia, acidosis, uraemic complications, fluid overload or pulmonary oedema despite medical treatment requires immediate nephrology/critical-care discussion.
Investigations
01Serial creatinine/eGFR, urea, sodium, potassium, bicarbonate and magnesiumFirst step
Why
Define AKI trajectory and treatment toxicity.
Interpretation and limitations
Interpret changes with baseline and timing; eGFR is less reliable in rapidly changing AKI, so do not dose or diagnose from one calculated value alone.
02Strict urine output, fluid balance and daily weight
Why
Measure perfusion and decongestion response.
Interpretation and limitations
Oliguria is a severity marker; weight/urine response helps distinguish ineffective diuresis from true volume depletion.
03Urinalysis and urine ACR/PCR or microscopy when indicated
Why
Find haematuria, proteinuria or intrinsic renal disease.
Interpretation and limitations
Active sediment or marked proteinuria is not explained by simple congestion and needs renal evaluation.
04Clinical congestion/perfusion assessment plus echocardiography
Why
Identify raised filling pressure, LV/RV function and shock/valve cause.
Interpretation and limitations
Raised JVP and venous congestion support continued decongestion; a small collapsible IVC measurement alone must not decide volume treatment.
Differential diagnosis
01
True volume depletion
Gastrointestinal loss, bleeding or over-diuresis can cause pre-renal injury. Low jugular venous pressure, postural symptoms, weight loss and improvement with carefully reassessed fluid favour underfilling over congestive nephropathy.
02
Intrinsic renal disease
Glomerulonephritis, interstitial nephritis or acute tubular injury may coexist with heart failure. Active urine sediment, substantial proteinuria or renal decline disproportionate to haemodynamics supports a primary renal process.
03
Urinary tract obstruction
Prostatic, ureteric or bladder-outflow obstruction can present with oliguria and rising creatinine. Urinary symptoms, a palpable bladder or hydronephrosis support the diagnosis and require prompt cause-specific management.
04
Expected haemodynamic medicine effect
Renin–angiotensin-system blockade or an SGLT2 inhibitor may cause an early haemodynamic fall in eGFR without structural kidney injury. Timing, blood pressure, volume status, potassium, urinalysis and the subsequent trajectory help distinguish this from progressive acute kidney injury.
Management
01First-lineDefine physiology and causeFirst stepFirst lineHF with worsening renal function+
1Confirm baseline and AKI trajectory; record urine output, weight, BP, JVP/oedema, perfusion and recent medicines/illness.
2Check electrolytes, bicarbonate, urinalysis, ECG and cause-directed imaging; consider sepsis, obstruction, bleeding and nephrotoxins.
3Stop NSAIDs and other avoidable renal insults; adjust renally cleared medicines and treat infection/obstruction promptly.
4Discuss early with HF and renal teams when eGFR <30, AKI is progressive or treatment goals conflict.
02Second-lineCongested and perfusedSecond lineRaised filling pressure with fluid overload despite renal decline+
1
Complications
01
Refractory congestion
Impaired sodium excretion and high filling pressures may produce pulmonary oedema, pleural effusions, ascites and peripheral oedema. Persistent congestion worsens breathlessness, renal function and hospitalisation risk.
02
Electrolyte and acid–base emergencies
Reduced renal clearance can cause dangerous hyperkalaemia and metabolic acidosis, with weakness, conduction disturbance or malignant arrhythmia. Refractory abnormalities may require renal-replacement assessment.
03
Low-output multiorgan failure
Severe cardiac dysfunction may progress to cardiogenic shock, oliguria, hepatic injury, lactic acidosis and cerebral hypoperfusion. Rapid recognition matters because fluid removal alone may worsen this phenotype.
04
Progressive chronic disease
Repeated acute episodes can accelerate chronic kidney and heart failure, narrow therapeutic tolerance and cause recurrent admission. Functional decline and mortality risk rise as both organs lose reserve.
Monitoring and follow-up
Daily or more frequent creatinine, urea, sodium, potassium, bicarbonate and magnesium during acute instability; use baseline and trajectory.
Hourly urine output in severe AKI/shock and daily weight plus strict intake/output during decongestion.
JVP, oedema/ascites, lung findings, BP/posture, perfusion and lactate to distinguish congestion from underfilling.
ECG for significant hyperkalaemia or arrhythmia and repeat potassium after emergency treatment.
ACEi/ARNI/ARB/MRA monitoring 1–2 weeks after start/increment and every 3–6 months once stable, plus any time renal function may be compromised.
At discharge: recovered/new renal baseline, medicine restart/titration plan, nephrotoxin advice and named HF/renal follow-up.
Special situations
Creatinine is not volume status
The same creatinine rise can occur during successful decongestion or harmful underfilling; examination and response determine the direction.
Loop diuretic wording matters
NICE says not to use it routinely to treat AKI, but to consider it when AKI coexists with fluid overload/oedema.
Renal replacement is complication-led
Refractory potassium, acidosis, uraemia or fluid overload determines urgency—not a single creatinine or urea cut-off.
Avoid permanent acute holds
A renin–angiotensin or SGLT2 medicine paused during shock/AKI needs an explicit reassessment and restart plan.
Venous pressure matters
Severe right-sided congestion can reduce GFR even when arterial BP looks acceptable.
Common pitfalls
01
Stopping all HF disease-modifying medicines for any creatinine increase without assessing size, potassium, BP or congestion.
02
Giving fluid to every oliguric HF patient despite raised JVP and oedema.
03
Calling high-dose loop diuretic a treatment for AKI rather than a treatment for overload.
04
Missing obstruction or intrinsic renal disease because HF is already diagnosed.
05
Delaying nephrology/critical-care referral until creatinine reaches an arbitrary number despite refractory pulmonary oedema or hyperkalaemia.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
CardiologyOriginal SBA
Rising creatinine during decongestion
A patient with acute HF remains markedly congested with raised JVP and oedema. After IV diuresis, symptoms begin to improve but creatinine rises modestly and BP/perfusion are stable. What is the best principle?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Do not automatically stop ACE inhibitor/ARNI/ARB/MRA for every small creatinine rise; reassess volume, BP, potassium and the current NICE threshold/action plan.
Under NICE 2025, renal function and electrolytes are checked before ACEi/ARNI/ARB/MRA, 1–2 weeks after starting and each increment, every 3–6 months once stable and whenever renal function may be compromised.
A creatinine increase over 50% or potassium over 5.5 mmol/L on ACEi/ARNI/ARB/MRA requires prompt repeat assessment of BP, volume, renal function, potassium, nephrotoxins and interacting potassium sources, with dose adjustment/temporary withholding and HF–renal advice as indicated; do not silently continue or permanently stop every class.
With eGFR 45 mL/min/1.73 m² or less, use lower starting doses/smaller increments for HF combinations; at eGFR below 30, NICE advises the HF MDT to consider renal liaison.
NSAIDs, dehydration, infection, obstruction, contrast and unreviewed potassium supplements/salt substitutes are common preventable accelerants.
05ECG and blood gas
Why
Detect hyperkalaemic electrical effects and severe acidosis/hypoperfusion.
Interpretation and limitations
Treat life-threatening hyperkalaemia immediately even before the full cause work-up; normal ECG does not make severe hyperkalaemia safe.
06Renal ultrasound
Why
Look for obstruction when the cause is uncertain or urinary obstruction is possible.
Interpretation and limitations
Urgently decompress infected obstruction or obstructed single kidney through urology/renal pathways.
Use IV loop diuretic for decongestion and titrate to urine, symptoms, weight and examination; it is treating overload, not AKI itself.
2If response is inadequate, increase loop exposure or use specialist sequential nephron blockade with close sodium/potassium monitoring.
3Do not stop prognostic HF therapy solely for a minor creatinine change; reassess BP, potassium and the magnitude/trajectory of change.
4Avoid routine ultrafiltration; reserve renal replacement for refractory complications after specialist assessment.
03Third-lineUnderfilled, hypotensive or shockedThird lineLow perfusion without dominant congestion+
1Hold further fluid removal, identify bleeding, sepsis, arrhythmia, RV infarction or medication-related hypotension and use small reassessed fluid only if true underfilling.
2Temporarily adjust BP-lowering or potassium-raising medicines when physiology or current safety thresholds require, with a documented restart plan.
3EscalationEscalate cardiogenic shock through critical-care/cardiology pathways and monitor lactate, urine and invasive BP.
4Restart and re-optimise beneficial HF therapy after stabilisation rather than allowing an acute hold to become permanent.
04EscalationSevere AKI or refractory complicationEscalationHyperkalaemia, acidosis, uraemia, anuria or pulmonary oedema not responding to medical therapy+
1Give immediate complication-specific treatment and contact nephrology/critical care; do not wait for a predetermined urea/creatinine value.
2Decide renal replacement from the whole clinical state and refractoriness, including fluid overload and haemodynamic tolerance.
3Choose intermittent versus continuous therapy according to haemodynamic stability and local critical-care/renal expertise.
4After recovery, reconcile drug doses, renal baseline, sick-day risks and the plan to restore HF disease-modifying therapy.
Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
Treats congestion and oedema in cardiorenal syndrome; not a treatment for intrinsic AKI.
Furosemide
Acute overload: if loop-naive, commonly 20–40 mg IV initially; if already taking loop diuretic, use an initial IV dose higher than the pre-admission oral dose and titrate to response. Chronic doses are individualised to the lowest effective level.
Monitor BP, urine, weight, creatinine, sodium, potassium and magnesium; high doses may be needed in CKD, but over-diuresis worsens hypoperfusion.
Prognostic HF therapy that should be preserved or restarted where safe.
Ramipril
HF commonly starts at 1.25 mg orally once daily and titrates toward 10 mg/day as tolerated; lower starting doses/smaller increments are considered when eGFR ≤45.
Potassium, renal function and BP monitoring; an acute hold may be needed with severe AKI, hypotension or hyperkalaemia, but document review/restart. Avoid ACEi plus ARB/ARNI.
MRA disease-modifying therapy when phenotype and safety permit.
Spironolactone
Usually 25 mg orally once daily in HF, with lower or alternate-day dosing according to renal function and potassium.
Hyperkalaemia and renal deterioration; do not start with unsafe potassium/renal status and monitor closely after every change.
Cardiac and renal disease-modifying therapy where licensed/NICE criteria apply.
Dapagliflozin
10 mg orally once daily for heart failure/CKD indications.
Expect a small early eGFR dip; assess volume. Interrupt during hospitalised major surgery or acute serious illness, monitor blood ketones and restart only after stabilisation and normal ketones.